Clinical Trial News and Research

RSS

Vitamin K appears to slow development of insulin resistance in elderly men

Vitamin K slowed the development of insulin resistance in elderly men in a study of 355 non-diabetic men and women ages 60 to 80 who completed a three-year clinical trial at the Jean Mayer Human Nutrition Research Center on Aging at Tufts University (USDA HNRCA).

26 Nov 2008

Researchers identify molecule that tells your brain your stomach is full

In studies with mice and rats, researchers have found that a chemical messenger called NAPE is made in the small intestine after the animals ate a greasy meal. After eating, NAPE - N-acylphosphatidylethanolamine, a mouthful in itself -- enters the blood and travels to the brain, where it quashes hunger signals.

26 Nov 2008

EpiVax receives grant for $390,000 to optimize HIV vaccine delivery

EpiVax, Inc., a leader in the field of computational immunology, announced today that it has received a grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to optimize delivery of an HIV vaccine.

26 Nov 2008

Ceregene announces data from phase 2 clinical trial of CERE-120 for Parkinson's

Ceregene, Inc., a biopharmaceutical company, today reported clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients with advanced Parkinson's disease.

26 Nov 2008

CardioVascular BioTherapeutics doses first patient in trial for severe coronary heart disease

CardioVascular BioTherapeutics, Inc. , announced today that it has dosed the first patient in North America (NA) as part of its ACORD Phase II clinical trial to treat patients with severe coronary heart disease.

25 Nov 2008

Potassium loss from blood pressure drugs increases diabetes risk by 50%

According to researchers in the U.S. the loss of potassium experienced from taking blood pressure drugs may explain higher risk of adult diabetes.

25 Nov 2008

Reliability of Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog) tool varies widely

A study published in the November issue of the Journal of Alzheimer's Disease (Volume 15:3) suggests the reliability of the Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog) may vary and possess the ability to affect clinical trial outcomes.

24 Nov 2008

Novel device enhances efficacy of standard chemotherapy

NovoCure Ltd. presented results yesterday evaluating the Novo-TTF device in vitro and in a pilot clinical trial that showed the device enhanced the efficacy of standard chemotherapy (temozolomide) treatment in newly-diagnosed glioblastoma multiforme (GBM) patients.

24 Nov 2008

Potassium loss caused by diuretics may explain higher risk of adult diabetes

Johns Hopkins researchers have discovered that a drop in blood potassium levels caused by diuretics commonly prescribed for high blood pressure could be the reason why people on those drugs are at risk for developing type 2 diabetes.

24 Nov 2008

Medarex starts phase 1b clinical trial with MDX-1106 for the treatment of cancer

Medarex, Inc. has announced it has initiated a Phase 1b clinical trial for MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody for the treatment of cancer.

24 Nov 2008

FDA accepts Labopharm's NDA for formulation of trazodone

Labopharm Inc. has announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA).

24 Nov 2008

New model predicts risk of recurrence in early stage colon cancer patients

Researchers in the Duke Institute for Genome Sciences & Policy have developed a model for predicting risk of recurrence in early stage colon cancer patients, and have used the model to also predict sensitivity to chemotherapy and targeted therapy regimens.

24 Nov 2008

Artemisinin combination therapies may be almost as effective as treated bednets in preventing malaria

Artemisinin combination therapies (ACTs) could be almost as effective in reducing transmission of malaria as insecticide-treated bednets (ITNs) in areas of low transmission, a study based on data from Tanzania has found. In high transmission areas, long-acting antimalarial regimens may be needed to achieve significant transmission reductions.

24 Nov 2008

Gefitinib just as effective as chemotherapy for lung cancer

Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by researchers at The University of Texas M. D. Anderson Cancer Center.

20 Nov 2008

FDA approves GSK's Promacta (Eltrombopag)

GlaxoSmithKline has announced that the United States Food and Drug Administration (FDA) granted accelerated approval for PROMACTA (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

20 Nov 2008

FDA approves Banzel (rufinamide) for Lennox-Gastaut syndrome

The U.S. Food and Drug Administration has approved a new drug, Banzel (rufinamide), for use as an adjunctive (add-on) treatment for seizures associated with Lennox-Gastaut syndrome.

20 Nov 2008

Bionovo to present phase 1B trial results of BZL101 in metastatic breast cancer

Bionovo, Inc. has announced the company will present results from the Phase 1B clinical trial of their lead drug candidate for advanced metastatic breast cancer, BZL101, at the Society for Integrative Oncology's Fifth International Conference in Atlanta, Georgia.

20 Nov 2008